|Bid||24.22 x 800|
|Ask||24.72 x 1100|
|Day's range||22.89 - 24.14|
|52-week range||20.60 - 99.27|
|Beta (5Y monthly)||2.12|
|PE ratio (TTM)||12.27|
|Earnings date||26 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||55.00|
InMode (NASDAQ: INMD) is proof that there isn't always a trade-off between stocks with great value and those with tremendous growth potential. This medical device maker has everything you'd expect from a value stock -- a low valuation, repeatable business model, and cost-sensitive management -- and it also has the strong revenue and earnings expansion of a monster growth stock. Let's analyze how and why InMode sports these positive features but is not as richly valued as a company like Tesla.
With growth of 267.4% in the last three years alone, the medical aesthetics company InMode (NASDAQ: INMD) is already well on the trajectory of being a 10-bagger. For InMode to grow by 10X, its market cap would need to expand from where it is now at around $2 billion to reach $21 billion by the middle of 2032. InMode is a technology-intensive company that makes workstations for medical aesthetics purposes like reducing fat deposits, toning muscles, and tightening skin.
InMode's sales and profits have boomed, but you wouldn't know it from the company's share price.